{
    "clinical_study": {
        "@rank": "51899", 
        "arm_group": [
            {
                "arm_group_label": "PE0139 Injection", 
                "arm_group_type": "Experimental", 
                "description": "Single subcutaneous injection of PE0139, 40 mg/mL"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a first-in-human randomized, double-blind (Investigator and subject), placebo\n      controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo\n      per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM)."
        }, 
        "brief_title": "Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus (T2DM)", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to sign a written informed consent and follow all study-related\n             procedures;\n\n          -  Male and female subjects  at least 18 years of age;\n\n          -  Male subjects and female subjects of childbearing potential must practice effective\n             contraception during the study and be willing and able to continue contraception for\n             30 days after their dose of study drug;\n\n          -  Body mass index \u226445 kg/m2;\n\n          -  Diagnosed with T2DM and who is currently taking a stable daily dose of a basal\n             insulin (Lantus)  plus at least one oral antihyperglycemic agent at a stable dose for\n             3 months prior to screening.\n\n        Exclusion Criteria:\n\n          -  Currently taking or have taken within 3 months prior to screening an approved or\n             investigational GLP-1 analogue/agonist (e.g., Victoza\u00ae) or pramlintide;\n\n          -  Currently taking or have routinely taken, within 3 months prior to screening , a\n             short-acting insulin;\n\n          -  Currently taking or have taken, within 3 months prior to screening, a long acting\n             insulin other than Lantus\u00ae;\n\n          -  Known allergy to, or serious adverse effect caused by an approved, or investigational\n             insulin product or any of its components;\n\n          -  Currently taking any of the following medications: thiazide or furosemide diuretics,\n             beta-blockers, estrogens or other hormonal replacement therapy, or other chronic\n             medications with known adverse effects on glucose tolerance levels unless the subject\n             has been on stable doses of such agents for at least 2 months prior to screening and\n             have no planned changes during the study period;\n\n          -  History of recurrent severe hypoglycemia (more than 2 episodes within the last 6\n             months prior to randomization or hypoglycemic unawareness;\n\n          -  Malignant disease defined as 1) any history of malignant melanoma or breast cancer\n             and/or 2) history of other types of cancer within the last 5 years prior to\n             screening;\n\n          -  Unstable cardiovascular disease defined as one or more of the following: History of\n             stroke, transient ischemic attack, or myocardial infarction within 6 months prior to\n             screening; History of or currently have New York Heart Association Class III-IV heart\n             failure prior to screening; Uncontrolled/sustained hypertension; History or evidence\n             of long QT syndrome or mean triplicate 12-lead electrocardiogram demonstrating QT\n             interval;\n\n          -  Clinically significant renal and/or hepatic dysfunction;\n\n          -  Absolute requirement for corticosteroids or have received systemic steroids within 3\n             months prior to Randomization (V5, Day -1). Note: Use of inhaled or topical\n             corticosteroids will be permitted;\n\n          -  Pregnant or lactating female subjects;\n\n          -  Known history of or active alcohol abuse or use of illicit drugs within 1 year prior\n             to screening;\n\n          -  Positive screening for human immunodeficiency virus antibodies, hepatitis B surface\n             antigen, or hepatitis C virus antibodies at V1;\n\n          -  Participating in any other study and have received any other investigational\n             medication or device within 30 days prior to Visit 1.\n\n          -  Other medical or psychiatric condition which, in the opinion of the Investigator,\n             would place the subject at increased risk."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835730", 
            "org_study_id": "PE0139-PT-CL-0001"
        }, 
        "intervention": [
            {
                "arm_group_label": "PE0139 Injection", 
                "intervention_name": "PE0139 Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36207"
                    }, 
                    "name": "Pinnacle Research Group, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33012"
                    }, 
                    "name": "Palm Springs Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Renton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98057"
                    }, 
                    "name": "Rainier Clinical Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Rainier Clinical Research", 
            "last_name": "Ronald Brazg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety will be evaluated by analyses of the change from baseline in vital signs.", 
                "measure": "Change in Vital Signs from baseline (Day 0 Pre-dose)", 
                "safety_issue": "Yes", 
                "time_frame": "Vital signs Day 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28"
            }, 
            {
                "description": "Safety will be evaluated by analyses of the change from baseline in 12-lead ECG.", 
                "measure": "Change in ECGs from baseline (Day -1)", 
                "safety_issue": "Yes", 
                "time_frame": "ECG Days 2 and 28"
            }, 
            {
                "description": "Safety will be evaluated by analyses of the safety laboratory parameters.", 
                "measure": "Change in Safety Labs from baseline (Pre-dose)", 
                "safety_issue": "Yes", 
                "time_frame": "Safety Labs Days 0, 7 and 28"
            }, 
            {
                "description": "Safety will be evaluated by the incidence and severity of immunogenicity.", 
                "measure": "Incidence and severity of immunogenicity", 
                "safety_issue": "Yes", 
                "time_frame": "Immunogenicity Days 0, 7, 14 and 28"
            }, 
            {
                "description": "Safety will be evaluated by the incidence and severity of adverse events including hypoglycemia.", 
                "measure": "Incidence and severity of adverse events including hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "As reported between Days -10 to 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835730"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetic parameters include: Area under the concentration curve from time 0 to infinity (AUC(0-inf)), Area under the concentration curve to the final sample with a concentration greater than or equal to Limit of Quantitation (LOQ) (AUC(0-t)), Time to maximum concentration (Tmax), Maximum serum concentration (Cmax), Elimination rate constant (Lambda-z), Elimination half-life (t1/2), Clearance uncorrected for bioavailability (CL/F), Distribution uncorrected for bioavailability (Vz/F)", 
                "measure": "Pharmacokinetic Profile", 
                "safety_issue": "No", 
                "time_frame": "Day 0, 1, 2, 3, 4, 5, 6, and 7"
            }, 
            {
                "description": "To assess the pharmacodynamic response (time action profile) of various single doses of PE0139.  Assessments include Fasting plasma glucose (FPG), 4-point serial glucose monitoring and glucose assessed by continuous glucose monitoring (CGM).", 
                "measure": "Pharmacodynamic Response", 
                "safety_issue": "No", 
                "time_frame": "FPG Day -10, -4, 0, 1, 2, 3, 4, 5, 6, 7, and 28; 4-pt Glucose and CGM - Day -10 to -7, -6, -5, and -4 to 7"
            }
        ], 
        "source": "PhaseBio Pharmaceuticals Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PhaseBio Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}